Published in AIDS Weekly, August 22nd, 2005
PA-457 is the first in a new class of HIV drugs called maturation inhibitors, with broad activity against HIV, including strains resistant to currently approved drugs, the most common cause of HIV treatment failure.
The key results of this phase 1/2 single dose study were reported previously at the 12th Conference on...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.